NCT04322617

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

Anlotinib With or Without Immune Checkpoint Inhibitors in Standard Chemo-immunotherapy Failed Advanced Non-small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 1,200 (estimated)
• Sponsor: Hunan Province Tumor Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.

Detailed description

This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC. The primary endpoint was PFS.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Anlotinib plus the same Immune Checkpoint Inhibitors.	Anlotinib, 8mg po qd, D1-D14 every 21days.
DRUG	Anlotinib plus the new Immune Checkpoint Inhibitors.	Anlotinib, 8mg po qd, D1-D14 every 21days.
DRUG	Anlotinib	Anlotinib, 8mg po qd, D1-D14 every 21days.

Timeline

• Start date: 2020-03-24
• Primary completion: 2028-03-24
• Completion: 2029-03-24
• First posted: 2020-03-26
• Last updated: 2024-06-04

Locations

1 site across 1 country: China